Biotech investment news September 2015: CaixaIpulse, Sanifit and Centauri Biotech

Integral service around a transaction
BY : Diego GutiérrezSeptember Thu, 2015
Good news for funding in the biotech sector in the first half of September, the largest round of funding in the history of Spanish biotechnology has been closed. CaixaImpulse has already announced its first 15 companies.



First edition of CaixaImpulse

A few months ago, in a post on new funds, we announced the appearance of the CaixaImpulse, an initiative of CaixaCapitalRisk for the creation of companies in the scientific field and yesterday, 15th September, the 15 projects selected in the first edition from among the 41 presented by different research centres, hospitals and universities were announced.

 For the selection of the projects, which belong to various communities: Andalusia (1), Catalonia (11), Galicia (1) Madrid (1) and Navarre (1), priority was given to the transfer potential of the assets and their impact on society.

To guarantee the success of the projects, CaixImpulse offers financial support (€50,000), training tailored to their needs and a immersion in market reality which will allow them to test their asset value proposition, adapt it and thus maximise the likelihood of a successful transfer.

Among the projects that have been selected we find a project froml CIMA which focuses on  The project will focus on the development of a new drug effective against haemorrhage and a project of the Institute for Bioengineering of Catalonia, which focuses on the treatment of chronic ulcers.

I2c Fund acquires Centauri Biotech

The Xunta de Galicia's venture capital company, Xesgalicia, has supported, through its I2C Fund, the biotech company Centauri Biotech, which develops veterinary pharmaceuticals.

I2C has acquired a 15% from the biotech company after underwriting a 50% of a capital increase 350,000 euros

Centauri Biotech, which they see as having great growth potential, is working on the development of drugs and treatments based on cell therapy and genetic diagnostics for inflammatory or degenerative joint-related lesions in animals. The company was founded in 2012 by four researchers.

"Xesgalicia I was already involved in another biotech company, Health in Code , a technology-based company that aims to identify health problems through the use of genetic diagnostics" says Diego Gutierrez of Abra-Invest.

Sanifit closes a €36M round

Sanifit Laboratories, a biopharmaceutical company dedicated to the development of a drug for the treatment of cardiovascular diseases related to calcification in dialysis-treated End Stage Renal Disease (ESRD) patients, has closed a €36.6m round led by Ysios Capital, with the participation of several international investors.

"This transaction is the largest round of financing for a Spanish company in the history of the biotech sector in Spain and one of the 10 largest in Europe so far this year," says Diego Gutierrez.

The capital increase will allow Sanifit to advance the clinical development of SNF472 to the end of phase IIb for the treatment of calcification-related cardiovascular diseases in patients with TRED and to phase II/III for the treatment of calciphylaxis.

If you are looking for financing, contact us. Abra-Invest has a team of experts in alternative financing at your disposal. Fill in the form or call us on +34 946024142


Other posts that may interest you 

Investment for the biotech sector: Tigenix, Ekuore and Grants4Apps



The M&A Professionals

Meet our services



Do you want to be up to date?


Our diferentiation

Market Research Technology
Our team of market analysis specialists is continuously analyzing the investments of the most active markets in the industry in order to unceasingly contribute ideas of the current market situation and identify the most relevant trends for senior management. We integrate the most relevant sources of information which allows us to discover the most interesting companies for venture capital and similarly helps us to identify the investors with the highest probability of involvement in an M&A process to ensure the success of our sell-side operations.

The reports and deductions of our advisors provide a broad view of the sector, both geographically and from the complementary or adjacent markets perspective.
Technology Data Analytics
for M&A
Advanced data anlytics is a weapon". Intelfin is an artificial intelligence tool we use for investing and creating value in SMEs through competitive analytics and the enterprise environment.

IntelFin consists of a cognitive system, which, through the application of advanced analytical technologies, facilitates the automation of investment and financing decisions in the field of non-listed companies and especially SMEs in high-growth sectors.

The information related to these companies is characterized by their lack of transparency and heterogeneity; thus, it is necessary to develop an advanced analysis which is as much predictive as prescriptive and is developed in a natural language custom, suitable to obtain greater clarity and knowledge of the investment scope.

The IntelFin system focuses especially on analyzing the variables that define and influence the competitive environment of a sector and the positioning of a company, analyzing their influence on future value creation. Therefore, IntelFin supports strategic decision-making to senior management by resolving questions such as:

¿What are my competitors' priorities, strategies and expansion plans? Who's my competition? Which competitor is most likely to grow at a higher rate?
Which areas of activity/business models will receive the most investment? Which sectors are most attractive to investors?
Which companies are going to experience the most growth in the near future? Which companies are most likely to receive investment or be acquired?
Training Methodology
We have developed training programs in an innovative set-up which guarantees our teams the acquisition of technical competences both in the field of corporate finance and in the field of psychology, that is much needed when it comes to negotiation processes.

We have a culture of continuous improvement of our processes, closely related to the use of information systems that allow the enhancement of internal communication between our teams, as well as external communication with our customers. Hence, we extend best practices identified internally in an efficient and rapid manner among our members.

Are you one of those who prefer to be well informed when making decisions?